ArticleScientific reports2026
Ultrasound-triggered amygdalin drug release across U-87 glioblastoma cell lines from gH625-tagged phase convertible nanodroplets.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ultrasound (US), as a non-invasive and non-ionising technology, has been utilized as an efficient technique for transporting drugs and genes across physiological barriers, such as the blood-brain barrier (BBB), in addition to its use in medical imaging. In Contrast-Enhanced Ultrasound Imaging (CEUS), microbubbles act as an effective delivery vehicle, thereby enhancing cellular uptake of the drug. This characteristic is attributed to the cavitation property of the microbubbles. In this study, we synthesised gH625-tagged pre-Polyglycerolsebacate encapsulating a perfluoropentane core (Pre-PGS-PFP) nanodroplets with improved internalisation properties and the ability to deliver a payload by phase converting to phase convertible nanodroplets upon insonation. Amygdalin, as an anticancerous drug, was loaded in the polymeric shell of Pre-PGS-PFP phase convertible nanodroplets using the solvent displacement method and was conjugated to the membrane-crossing peptide (gH625) using NHS-EDC coupling. The nanodroplets were physicochemically characterized using FTIR, SEM, confocal microscopy and zeta analysis. The nanodroplets were found to load 80.10% of Amygdalin. Cytotoxicity and uptake studies in U87 glioblastoma cells demonstrated that ultrasound-triggered amygdalin release significantly enhanced cell death compared to diffusion-based release or treatment with free Amygdalin. Furthermore, the presence of gH625 further improved cellular uptake due to its membrane-penetrating ability. Overall, the synergistic effect of ultrasound activation and gH625 functionalization facilitated efficient internalization and localized drug release, suggesting a promising strategy for targeted delivery and therapeutic enhancement in the treatment of glioblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.